Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Seeking Alpha
The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Pharmaceuticals and one it should have exclusive access to for some years. However, to maintain its "first mover" advantage, the company has to launch the drug effectively and keep an eye on future competitors. We take a more detailed look at Madrigal Pharmaceuticals and the challenges ahead in the paragraphs below. Today, we put mid-cap concern Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL in the spotlight. The company's lead candidate resmetirom (known by the brand name Rezdiffra) garnered the first FDA approval for a liver condition called nonalcoholic steatohepatitis, or NASH, in March. To Recommended For You Recommended For You About MDGL Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label [Seeking Alpha]Seeking Alpha
- Madrigal Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024GlobeNewswire
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.MarketBeat